Reports
Sale
Cancer Pain Market Size, Share, Trends, Analysis, Report: By Drug Type: Opioids, Non-Opioids, Nerve Blockers; By Indication Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Others; By Treatment Type: Immunotherapy, Chemotherapy, Targeted Therapy, Others; Regional Analysis; Supplier Landscape; 2024-2032
Cancer Pain Market Outlook
The cancer pain market size was valued at USD 6.53 billion in 2023, driven by the growing demand for effective therapeutics to manage cancer pain across the 8 major markets. The market is expected to grow at a CAGR of 6.10% during the forecast period of 2024-2032, with the values likely to rise from USD 6.93 billion in 2024 to USD 11.12 billion by 2032.
Cancer Pain Market Overview
Cancer pain can result from a tumor pressing on organs, nerves, or bones. It can also be caused by cancer treatments or surgery. The severity of pain can differ depending on factors such as the type of cancer and its stage. The rising prevalence of cancer necessitates the need for effective therapeutics to manage cancer pain. With the global burden of new cancer cases predicted to reach approximately 30 million by 2040 , the cancer pain market demand is anticipated to surge in the forecast period.
The increased impetus for research activities to address the growing need for cancer pain treatment solutions has bolstered market growth. Intensive research efforts are paving the way for potential therapeutics. According to a study published in BMJ Supportive & Palliative Care in May 2023, medical cannabis was revealed to be safe and effective for treating cancer-related pain. Further, the use of medical cannabis reduced the use of opioids and other pain medications by almost 32%. Thus, the introduction of such products in cancer patients’ pain regimens is likely to augment the cancer pain market growth.
The market is also driven by the rising healthcare expenditure to treat cancer-associated pain as well as various initiatives and programs launched by the government to raise awareness regarding the condition. Moreover, the rising geriatric population with increased susceptibility to cancer pain will also help in the market growth.
Cancer Pain Market Segmentation
Market Breakup by Drug Type
- Opioids
- Fentanyl
- Morphine
- Others
- Non-Opioids
- Acetaminophen
- Non-Steroidal Anti-Inflammatory Drug
- Nerve Blockers
Based on the drug type, the market is divided into opioids, non-opioids, and nerve blockers. Opioids such as fentanyl and morphine, among others, can help manage moderate to severe pain. Non-opioids like acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammation and block pain signals without targeting opioid receptors. Nerve blockers help in blocking nerve signals responsible for pain transmission.
Market Breakup by Indication Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Blood Cancer
- Others
The market segmentation by indication type includes lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. The rising prevalence of different types of cancer is fueling the cancer pain market share.
Market Breakup by Treatment Type
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
The market segmentation by treatment type comprises immunotherapy, chemotherapy, targeted therapy, and hormonal therapy. Each treatment type has unique mechanisms of action as well as potential side effects.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The market report covers 8 major markets poised to witness significant growth in upcoming years. The region-based segmentation of the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America dominates the market which can be attributed to the rising geriatric population, the presence of an advanced healthcare system, and the increased prevalence of cancer in the region.
Cancer Pain Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Eli Lilly
- HISAMITSU PHARMACEUTICAL CO., INC.
- Aoxing Pharmaceutical Company, inc.
- GRÜNENTHAL PHARMA GmbH & CO. KG
- PFIZER INC.,
- BIODELIVERY SCIENCES INTERNATIONAL, INC.
- OREXO AB
- Johnson and Johnson
- Medtronic plc
- Novartis AG
- Glaxo SmithKline Plc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Indication Type |
|
| Breakup by Treatment Type |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Cancer Pain Market Report
- How will the market landscape evolve in the coming years?
- What are the major market trends influencing the market?
- What are the major drivers, opportunities, and restraints in the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do factors such as the rising prevalence of cancer impact market growth?
- What are the different types of cancer pain treatments available in the market?
- What are the latest advancements in cancer pain drug research and development?
- What were the major drug approvals to manage cancer pain during the historical period?
- Which segment has the major impact on the cancer pain market size?
- What investments and funding are driving research and development in the market?
- What are the key strategies adopted by leading pharmaceutical companies to gain market share?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Pain Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Pain Epidemiology Analysis – 8MM
5.1 8MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Cancer Pain Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
5.3.1 Germany Cancer Pain Epidemiology Forecast (2017-2032)
5.3.2 France Cancer Pain Epidemiology Forecast (2017-2032)
5.3.3 Italy Cancer Pain Epidemiology Forecast (2017-2032)
5.3.4 Spain Cancer Pain Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
5.4 Japan Cancer Pain Epidemiology Forecast (2017-2032)
5.5 India Cancer Pain Epidemiology Forecast (2017-2032)
6 Cancer Pain Market Overview – 8MM
6.1 Cancer Pain Market Historical Value (2017-2023)
6.2 Cancer Pain Market Forecast Value (2024-2032)
7 Cancer Pain Market Landscape – 8MM
7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cancer Pain Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Indication Type
7.2.3 Analysis by Treatment Type
8 Cancer Pain Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Cancer Pain Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Cancer Pain Market Segmentation – 8MM
11.1 Cancer Pain Market by Drug Type
11.1.1 Market Overview
11.1.2 Opioids
11.1.2.1 Fentanyl
11.1.2.2 Morphine
11.1.2.3 Others
11.1.3 Non-Opioids
11.1.3.1 Acetaminophen
11.1.3.2 Non-Steroidal Anti-Inflammatory Drugs
11.1.4 Nerve Blockers
11.2 Cancer Pain Market by Indication Type
11.2.1 Market Overview
11.2.2 Lung Cancer
11.2.3 Colorectal Cancer
11.2.4 Breast Cancer
11.2.5 Prostate Cancer
11.2.6 Blood Cancer
11.2.7 Others
11.3 Cancer Pain Market by Treatment Type
11.3.1 Market Overview
11.3.2 Immunotherapy
11.3.3 Chemotherapy
11.3.4 Targeted Therapy
11.3.5 Hormonal Therapy
11.4 Cancer Pain Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Cancer Pain Market
12.1 Cancer Pain Market Historical Value (2017-2023)
12.2 Cancer Pain Market Forecast Value (2024-2032)
12.3 Cancer Pain Market by Drug Type
12.4 Cancer Pain Market by Indication Type
13 EU-4 and United Kingdom Cancer Pain Market
13.1 Cancer Pain Market Historical Value (2017-2023)
13.2 Cancer Pain Market Forecast Value (2024-2032)
13.3 Germany Cancer Pain Market Overview
13.3.1 Cancer Pain Market by Drug Type
13.3.2 Cancer Pain Market by Indication Type
13.4 France Cancer Pain Market Overview
13.4.1 Cancer Pain Market by Drug Type
13.4.2 Cancer Pain Market by Indication Type
13.5 Italy Cancer Pain Market Overview
13.5.1 Cancer Pain Market by Drug Type
13.5.2 Cancer Pain Market by Indication Type
13.6 Spain Cancer Pain Market Overview
13.6.1 Cancer Pain Market by Drug Type
13.6.2 Cancer Pain Market by Indication Type
13.7 United Kingdom Cancer Pain Market Overview
13.7.1 Cancer Pain Market by Drug Type
13.7.2 Cancer Pain Market by Indication Type
14 Japan Cancer Pain Market
14.1 Cancer Pain Market Historical Value (2017-2023)
14.2 Cancer Pain Market Forecast Value (2024-2032)
14.3 Cancer Pain Market by Drug Type
14.4 Cancer Pain Market by Indication Type
15 India Cancer Pain Market
15.1 Cancer Pain Market Historical Value (2017-2023)
15.2 Cancer Pain Market Forecast Value (2024-2032)
15.3 Cancer Pain Market by Drug Type
15.4 Cancer Pain Market by Indication Type
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 India CDSCO
16.1.4 JAPAN PMDA
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnerships and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Eli Lilly
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 HISAMITSU PHARMACEUTICAL CO., INC.,
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Aoxing pharmaceutical company, inc.,
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 GRÜNENTHAL PHARMA GmbH & CO. KG
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 PFIZER INC.,
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 BIODELIVERY SCIENCES INTERNATIONAL, INC.,
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 OREXO AB
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Johnson and Johnson
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Medtronic plc
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Novartis AG
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Glaxo SmithKline Plc
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
23 Cancer Pain Market- Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 6.53 billion in 2023 driven by the growing demand for effective therapeutics to manage cancer pain across the 8 major markets.
The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032, likely to reach a market value of USD 11.12 billion by 2032.
The increasing of incidence of cancer along with heightened patient awareness and healthcare expenditure are fuelling the market demand for cancer pain therapeutics.
One of the significant trends in the market is the intensive research activities to develop effective treatment solutions to manage cancer pain. Alternative therapies such as medical cannabis are being researched to develop personalised and efficient solutions for patients.
Based on the drug type, the market is divided into opioids, non-opioids, and nerve blockers. Opioids include fentanyl and morphine, among others. Non-opioids include acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs).
The market segmentation by indication type includes lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others.
The market segmentation by treatment type comprises immunotherapy, chemotherapy, targeted therapy, and hormonal therapy.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are Eli Lilly, Hisamitsu Pharmaceutical CO., INC., Aoxing Pharmaceutical Company, Inc., Grünenthal Pharma GmbH & CO. KG, Pfizer Inc., Biodelivery Sciences International, Inc., OREXO AB, Johnson and Johnson, Medtronic plc, Novartis AG, and Glaxo SmithKline Plc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER